HIPAA Alert: Potential Data Breach Learn More

Search
Close this search box.

Oncology Business Review Interviews Dr. Andrew Pecora

Andrew Pecora, MD, FACP, CPE, is President of the newly formed Regional Cancer Care Associates—a statewide group of 76 oncologists who have consolidated their practices into a new oncology network in New Jersey. This new network is supported by 500 employees at 20 cancer care delivery sites that stretches from Cape May in the south all the way up to the northern part of the state, and includes the state-of-the-art John Theurer Cancer Center at Hackensack University Medical Center where Dr Pecora is vice president of cancer services. Size matters in today’s environment, and the new network provides care to more than 17,000 new patients annually, in addition to the 230,000 patients that already participate in the provider network. Regional Cancer Care Associates is a “value-based? cancer care network that will allow the network to bargain as a group with insurance companies and drug companies to provide quality cancer care to patients while reducing the cost of that care.

Although each participating practice will retain autonomy in terms of making specific medical decisions for the care of their patients, a doctor-dominated board of trustees will standardize that care—meaning, for example, that the trustees will decide how many diagnostic tests are to be ordered or decide on the effectiveness of certain chemotherapies for treatment. When we heard about the creation of a new network, we thought it would be important to discuss the details with Dr. Pecora…[read more]

we are here for you

For more information or to schedule an appointment,
call 844-346-7222. You can also schedule an appointment by calling the RCCA location nearest you.

RELATED ARTICLES

Regional Cancer Care Associates is one of fewer than 200 medical practices in the country selected to participate in the Oncology Care Model (OCM); a recent Medicare initiative aimed at improving care coordination and access to and quality of care for Medicare beneficiaries undergoing chemotherapy treatment.